protocolSection identificationModule nctId: NCT06283082, orgStudyIdInfo id: 69HCL23_0617, secondaryIdInfos id: ID-RCB, type: OTHER, domain: 2023-A01406-39, briefTitle: Oxalate Excretion Profile in Patients With a Heterozygous Mutation of the AGXT (Alanine-glyoxylate Aminotransferase) Gene, acronym: HETEROX, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Hospices Civils de Lyon, class: OTHER, descriptionModule briefSummary: Primary hyperoxaluria type I (PH1) is a rare genetic disorder responsible for severe lithiasis leading to progressive deterioration of renal function and end-stage renal failure. PH1 is linked to a deficiency in glyoxylate amino transferase (AGXT), which leads to increased endogenous oxalate synthesis and hyperoxaluria. In the urine, urinary oxalate precipitates with calcium, forming insoluble crystals, leading to lithiasis and the development of nephrocalcinosis.Non-genetic etiologies of oxalic nephropathy are well known, in particular enteric causes (malabsorptions, bypass, calcium deficiencies, etc.) and sometimes linked to increased oxalate intake in the form of nutritional or vitamin supplements, reinforcing the hypothesis of probably underestimated favouring factors of hyperoxaluria.Until now, heterozygous patients with a mutation in the AGXT gene were considered asymptomatic. However, there have been several cases of patients with heterozygous AGXT mutations presenting with lithiasis.Consequently, the characteristics of symptomatic and asymptomatic heterozygous patients will be studied in order to define the elements that would explain the expression of the disease (particularities of the AGXT mutation, presence of another heterozygous mutation or favorable living conditions).The hypothesis is that there is an increase in hepatic oxalate production in heterozygous patients, which explains why they remain asymptomatic under usual conditions, but could favor stone formation under favorable conditions such as severe calcium deficiency or malabsorption., conditionsModule conditions: Hyperoxaluria (Disorder), designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Lithiasis assessment, outcomesModule primaryOutcomes measure: Urinary oxalate and glycolate excretion, secondaryOutcomes measure: The prevalence of stones, secondaryOutcomes measure: Lithiasis disease severity, secondaryOutcomes measure: Lithiasis disease severity, secondaryOutcomes measure: Lithiasis disease severity, secondaryOutcomes measure: Lithiasis disease severity, secondaryOutcomes measure: Predisposing conditions for lithiasis disease, secondaryOutcomes measure: Predisposing conditions for lithiasis disease, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CLIMA, pavillon R, Hôpital Edouard Herriot, city: Lyon, zip: 69003, country: France, contacts name: Laurence Derain, MD,PhD, role: CONTACT, phone: 04 72 11 91 17, phoneExt: +33, email: laurence.derain@chu-lyon.fr, geoPoint lat: 45.74848, lon: 4.84669, hasResults: False